DoD COVID-19 Vaccine Distribution Operational Planning Team (OPT)
7700 Arlington Blvd
Falls Church, Virginia 22042
16 December 2020

Modification (MOD) 01 to Department of Defense Coronavirus Disease 2019 Vaccination Plan (DoD COVID-19 Vaccination Plan)

References: **ADD.**

m. MOD 03 to Revision 01 to DoD Response to Coronavirus-2019, CJCS EXORD/DTG: 120459Z Dec 20

n. Pfizer-BioNTech COVID-19 Vaccine Letter of Authorization, 11 DEC 2020

o. Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Health Care Providers (HCP), 11 DEC 2020

p. Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers, 11 DEC 2020

q. Center for Disease Control and Prevention (CDC), Morbidity and Mortality Weekly Report (MMWR) Early Release/Vol.69, The Advisory Committee on Immunization Practices' (ACIP) Interim Recommendation fur Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020, December 13, 2020.

Narrative (U) **ADD**.

This is a Director Defense Health Agency (DHA)-approved Modification (MOD) that directs Department of Defense (DoD) Components to transition from Phase 1 to Phase 2A to commence COVID-19 vaccination program in accordance with (IAW) DHA-Interim Procedures Memorandum (IPM) 20-004 "DoD Coronavirus Disease (COVID)-19 Vaccination Program (CVP) Implementation" (Appendix 5 to Annex C), and available at: https://health.mil/Reference-Center/Policies.

1. (U) **Situation**.

a. (U) General. **ADD**. On, 11 December 2020, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the Food and Drug Administration (FDA) authorize the use of the Pfizer vaccine and the FDA authorized the vaccine under an Emergency Use Authorization (EUA).

b. (U) Publication of DHA-IPM 20-004 CVP (Appendix 5 to Annex C) transitions the Department from Phase 1 (Pre-vaccination) to Phase 2A (Controlled Pilot/Limited Distribution).

2. (U) **Mission**. No Change.

3. (U) **Execution.**

3.a.3. (U) **Phase 2A Controlled Pilot/Limited Distribution. ADD.** During Phase 2A, additional sites will be required to order vaccine, at the direction of the Military Departments, NGB, USCG, and DHA, to prepare for Phase 2B.

3.a.3. (U) OCONUS

- Tripler Army Medical Center (TAMC), Honolulu, Hawaii. **ADD.**

- Redistribute to Schofield Barracks (Army), Naval Health Clinic Hawaii (Navy), Hawaii National Guard, USCG Base Honolulu, and Joint Base Pearl Harbor-Hickam (Air Force), Honolulu, Hawaii

- Camp Carroll, Republic of Korea (USAMMC-K). **CHANGE.**

- Redistribute to Camp Humphreys, Osan Air Base, Kunsan Air Base, K16 Air Base, Walker Air Base, Camp Casey, South Korea

3.a.3. **REPLACE.**

(U) Figure 2. Pilot Site Location Vaccine Distribution Plan

Pilot Site Distribution Facility	Location	State/ Country	Ultra Cold (Pfizer)	# Doses 1st allocation	# Doses redistributed Seconda	# Doses redistributed Tertiary	Frozen (Moderna)	# Doses 1st allocation	# Doses redistributed Secondar
CONUS									
Darnall Army Medical Center	Fort Hood	TX	-80°	3900					
Wilford Hall	Joint Base San Anton	TX	-80°	4875					
Brooke Army Medical Center	Joint Base San Anton	TX	-80°		*2925				
Madigan Army Medical Center	Joint Base Lewis McC	WA	-80°	3900					
Womack Army Medical Center	Fort Bragg	NC	-80°	3900					
Naval Hospital Jacksonville	NAS Jacksonville	FL	-80°	2925					
Base Alameda Health Services (Clinic)	USCG Base Alameda	CA	-80°	975					
Naval Medical Center	San Diego	CA	-80°	4875					
Naval Hospital	Camp Pendleton	CA	-80°		*1950				
Naval Hospital Pensacola	Pensacola	FL	-80°	1950					
Keesler AFB	Keesler	FL	-80°		*975				
Armed Forces Retirement Home	Gulfport (Keesler AFE	MS	-80°			**635			
Walter Reed National Military Medical C	Bethesda	MD	-80°	5850					
Armed Forces Retirement Home	Washington	DC	-80°		*560				
Portsmouth Naval Medical Center	Portsmouth	VA	-80°	4875					
US Coast Guard Base Clinic	Portsmouth	VA	-80°		*975				
Indiana National Guard Medical Detach	Franklin	IN	-80°	975					
New York National Guard Medical Com	Watervliet	NY	-80°	975					
OCONUS									
Tripler Army Medical Center (TAMC)	Honolulu	HI	-80°	3900	as required				
USAMMC-K		Korea			as required		-20°	3500	*3500
USAMMC-E		Germany					-20°	1600	
Landstuhl Regional Medical Center	Landstuhl	Germany					-20°		*1600
TLAMM-P		Japan					-20°	1100	
Kadena Medical Facility	Kadena AB	Japan					-20°		*1100
*Quantity redistributed out of initial site total									
**Quantity redistributed out of secondary site total									

3.a.4. (U) **Phase 2B. - Expanded Distribution. ADD.** Phase 2B is pro-rata, by Military Department, USCG, NGB, and DHA, based on Service end-strength

and DHA responsibilities. Current pro-rata is Department of the Army 30%; Department of the Navy 28% (Navy 18%, USMC 10%); Department of the Air Force 18% (including U.S. Space Force); Coast Guard 2%; National Guard Bureau (Army/Air Guard) 20%; and, Defense Health Agency 2%.

b. (U) Tasks. **ADD**.

(1) (U) DoD COVID-19 Task Force (CVTF). No Change.

(2) (U) Secretaries of Military Departments, Chief of the NGB, and Commandant of the USCG. ADD.

(bb) (U) PH2A: Notify additional vaccination sites to place vaccine orders.

(cc) (U) PH2B: Receive verified pro-rata allocation from DoD Vaccine OPT and distribute to vaccine sites, as appropriate.

(dd) (U) Be prepared to order and issue COVID-19 vaccine to support defense agencies and activities in and around MTF geographic cachment areas upon presentation of defense agency activity requirements.

(3) (U) Combatant Commands. No change.

(4) (U) USCENTCOM. No Change.

(5) (U) USEUCOM. No Change.

(6) (U) USINDOPACOM. No Change.

(7) (U) Defense Agencies. ADD.

(f) (U) Direct liaison authority (DIRLAUTH) to coordinate with local, supporting MTF to provide vaccine requirement by tier (Ref: Annex C, Appendix 1) and location, and coordinate vaccination, as appropriate.

(8) (U) Defense Health Agency. ADD.

(oo) (U) Participate in CDC COVID-19 Vaccine Safety Team and elevate any recurrent clinical concerns to the DoD Joint Preventive Medicine Policy Group.

(pp) (U) Receive verified pro-rata allocation from DoD Vaccine OPT and distribute to vaccine sites, as appropriate.

(qq) (U) PH2A: Notify additional vaccination sites to place vaccine orders.

(8) (U) Defense Health Agency. REPLACE.

(dd) (U) PH2B: Authorize geographic distribution and redistribution (as required), by DHA-owned vaccination sites (i.e. DHA Markets) of allocated COVID-19 vaccines.

(9) (U) Defense Logistics Agency. No Change

(10) (U) USAMMA-DOC. No Change.

(11) (U) Vaccination Sites. ADD.

(z) (U) Utilize procedures outlined in Annex Q, Appendix 5 (AHLTA, ASIMS, MEDPROS, MRRS) and Annex Q, Appendix 6 (MHS GENESIS) for documentation of the COVID-19 vaccine.

(aa) (U) Ensure all vaccination sites staff refer to and comply with Pfizer COVID-19 Vaccine EUA published documents and any updates, as appropriate (Refs N, O, & P). References can be found at:
https://www.fda.gov/media/144412/download,
https://www.fda.gov/media/144413/download,
https://www.fda.gov/media/144414/download

(11) (U) Vaccination Sites. REPLACE.

(m) (U) PH2A: Designated redistribution sites (as identified in Figure 2), support redistribution of COVID-19 vaccines ICW installation management support activities.

c. (U) Coordinating Instructions. **ADD.**

(16) (U) Comply with all vaccine handling, storage and administrative requirements outlined in the DHA IPM (Appendix 5 to Annex C) and available on the DHA Immunization Health Division website: www.health.mil/vaccines

(17) (U) Ensure all stakeholders refer to and comply with Pfizer COVID-19 Vaccine EUA published documents and any updates, as appropriate (Refs N, O, & P). References can be found at:
https://www.fda.gov/media/144412/download,

https://www.fda.gov/media/144413/download,
https://www.fda.gov/media/144414/download

(18) (U) Military Services, NGB, USCG, and DHA will maintain asset visibility through USAMMA-DOC and DLA Service representatives.

4. (U) **Administration and Logistics**. No Change.

5. (U) **Command and Control**. No Change.

5.a. (U) Command Relationships. **ADD.**

(6) (U) Secretary of Defense delegated authority to DHA for coordination with DoD Components to modify any provisions of the COVID-19 vaccination plan (Ref M).

(7) (U) Transition between Operational Phases (i.e. 2A, 2B, and 2C) is at the discretion of the DHA Director.

(8) (U) Allocation of vaccine to DoD Components in operational Phase 2B is delegated to the Secretaries of the Military Departments, Chief of the NGB, Commandant of the USCG, and DHA Director, ICW USAMMA-DOC.

Annexes/Attachments: **ADD.**

C – Operations.
Appendix 5. (U) DHA-Interim Procedure Memorandum (IPM) 20-004DoD Coronavirus Disease (COVID)-19 Vaccination Program (CVP) Implementation
Appendix 6. (U) Mass Vaccination Technical Guide (MHS Genesis) V 0.3, October 2020.
FILE NAME: "Annex C, Appendix 6 Pilot Site Distribution Plan (Week 2)"
Q – Health Services.
Appendix 5. (U) Mass Immunizations Workflow Guide v4.1(U) Appendix 6. (U) MHS Genesis Workflow Guide (U).
FILE NAME: “Annex Q Appendix 6 Mass Vaccinations Technical Guide for Use with MHS Genesis”

Annexes/Attachments: **UPDATE. .**
C – Operations. Appendix 4. (U) Decision Point to CCIR Crosswalk v.2

PLACE.RONALD.JOSEPH.1146823900
Digitally signed by PLACE.RONALD.JOSEPH.1146823900
Date: 2020.12.17 10:36:22 -05'00'

RONALD J. PLACE
LTG, MC, USA
DIRECTOR